PubMed COVID-19 Clinical Care

Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years

Monday, May 22, 2023 - 4:00 AM

CONCLUSIONS AND RELEVANCE: Among 20 health outcomes that were monitored in near real time, a safety signal was identified for only myocarditis or pericarditis. Consistent with other published reports, these results provide additional evidence that

SIRSi-vaccine dynamical model for the Covid-19 pandemic

Monday, May 22, 2023 - 4:00 AM

Covid-19, caused by severe acute respiratory syndrome coronavirus 2, broke out as a pandemic during the beginning of 2020. The rapid spread of the disease prompted an unprecedented global response involving academic institutions, regulatory agencies

SARS-CoV-2 inhibition and specific targeting of infected cells by VSV particles carrying the ACE2 receptor

Sunday, May 21, 2023 - 4:00 AM

No abstract

Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials

Sunday, May 21, 2023 - 4:00 AM

BACKGROUND: NVX-CoV2373 (Nuvaxovid™ or the Novavax COVID-19 Vaccine, Adjuvanted), the first protein-based COVID-19 vaccine, received emergency use authorization (EUA) as a primary series/booster and is available globally. NVX-CoV2373 primary series

Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 SARS-CoV-2 Primary Vaccination

Sunday, May 21, 2023 - 4:00 AM

CONCLUSIONS: NVX-CoV2373 elicits a moderately Th1-biased CD4+ T-cell response that is cross-reactive with ancestral and variant S proteins after 2 doses.